Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2019 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for
zometa ft
Your search for
vometa-ft
retrieved no results
Designing of Stable Co-crystals of Zoledronic Acid Using Suitable Coformers.
Chem Pharm Bull (Tokyo). 2019;67(8):816-823. doi: 10.1248/cpb.c19-00202.
Chem Pharm Bull (Tokyo). 2019.
PMID: 31366831
Free article.
In this present study a new co-crystals of zoledronic acid with DL-tartaric acid and nicotinamide has been developed with improved solubility. Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and lo …
In this present study a new co-crystals of zoledronic acid with DL-tartaric acid and nicotinamide has been developed wi …
Biomolecular fingerprints of the effect of zoledronic acid on prostate cancer stem cells: Comparison of 2D and 3D cell culture models.
Güler G, Acikgoz E, Mukhtarova G, Oktem G.
Güler G, et al.
Arch Biochem Biophys. 2024 Mar;753:109920. doi: 10.1016/j.abb.2024.109920. Epub 2024 Feb 1.
Arch Biochem Biophys. 2024.
PMID: 38307315
In the current study, the drug response of prostate cancer stem cells (PCSCs) to zoledronic acid (ZOL) grown in two-dimensional (2D) and three-dimensional (3D) culture systems was compared using Fourier transform-infrared (FT-IR) spectroscopy which is a vibra …
In the current study, the drug response of prostate cancer stem cells (PCSCs) to zoledronic acid (ZOL) grown in two-dimensiona …
Item in Clipboard
GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T.
Hadji P, et al.
Osteoporos Int. 2016 Oct;27(10):2967-78. doi: 10.1007/s00198-016-3623-6. Epub 2016 May 12.
Osteoporos Int. 2016.
PMID: 27172934
Free PMC article.
RESULTS: Two-year persistence with denosumab was significantly higher than with i.v. or oral bisphosphonates (39.8 % [n = 21,154] vs 20.9 % [i.v. ibandronate; n = 20,472] and 24.8 % [i.v. zoledronic acid; n = 3966] and 16.7-17.5 % [oral bisphosphonates; n = 114,401] …
RESULTS: Two-year persistence with denosumab was significantly higher than with i.v. or oral bisphosphonates (39.8 % [n = 21,154] vs 20.9 % …
Item in Clipboard
Cite
Cite